Skip to main content

FHTX

Stock
Health Care
Biotechnology

Performance overview

FHTX Price
Price Chart

Forward-looking statistics

Beta
1.20
Risk
91.67%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Foghorn Therapeutics Inc is engaged in the discovery and development of a new class of medicines targeting genetically determined dependencies within the chromatin regulatory system. Its proprietary Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing it to identify, validate, and potentially drug targets within the system. The company is developing FHD-286, a selective, allosteric ATPase inhibitor, and FHD-609, a protein degrader, to treat hematologic cancers and solid tumors.

Company info

SectorHealth Care
IndustryBiotechnology
Employees141
Market cap$332.5M

Fundamentals

Enterprise value$76.2M
Revenue$23.5M
Revenue per employee—
Profit margin0.00%
Debt to equity-0.57

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)-$1.29
Dividend per share—
Revenue per share$0.39
Avg trading volume (30 day)$831K
Avg trading volume (10 day)$1M
Put-call ratio—

Macro factor sensitivity

Growth+6.3
Credit+1.7
Liquidity-2.5
Inflation+1.7
Commodities+4.6
Interest Rates-1.5

Valuation

Dividend yield0.00%
PEG Ratio-3.25
Price to sales12.17
P/E Ratio-3.25
Enterprise Value to Revenue3.24
Price to book-5.23

Upcoming events

Next earnings dayMay 14, 2025
Next dividend day—
Ex. dividend day—

News

Foghorn Therapeutics Inc. (FHTX) Reports Q1 Loss, Misses Revenue Estimates

Foghorn Therapeutics Inc. (FHTX) came out with a quarterly loss of $0.30 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.59 per share a year ago.

Zacks Investment Research (May 14, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free